GlassScriptPhysician profile
Mahe Otero
NPI 1629648514
$3,802.44
in general payments reported to CMS, 2019-2025
46 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $397 · 2022: $588 · 2024: $296 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.27 |
| Education | $297.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $287.84 | 2024-2025 | Jakafi |
| Astellas Pharma US INC | $265.65 | 2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $253.85 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Amgen INC. | $252.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $247.13 | 2022 | |
| Janssen Biotech, INC. | $183.45 | 2024-2025 | Rybrevant, Erleada, Akeega |
| Novocure INC. | $147.55 | 2021 | |
| Pfizer INC. | $144.79 | 2025 | |
| Merck Sharp & Dohme LLC | $141.19 | 2025 | Keytruda, Welireg |
| Exelixis INC. | $130.11 | 2021 | |
| Kyowa Kirin, INC. | $119.14 | 2021 | |
| Pharmaessentia USA Corporation | $117.18 | 2025 | Besremi |
| Sobi, INC | $114.76 | 2024-2025 | |
| Daiichi Sankyo INC. | $98.56 | 2025 | Datroway, Vanflyta, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $89.37 | 2025 | Alunbrig, Advate, Fruzaqla |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $78.54 | 2025 | Braftovi, Tukysa, Mektovi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.12 | 2024-2025 | Gilotrif |
| Lilly USA, LLC | $74.98 | 2024-2025 | Jaypirca, Verzenio |
| Beone Medicines USA, INC. | $67.38 | 2025 | Brukinsa, Tevimbra |
| Dendreon Pharmaceuticals LLC | $64.45 | 2025 | Provenge |
| Genmab U.S., INC. | $62.35 | 2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $57.94 | 2025 | Libtayo, Lynozyfic |
| Abbvie INC. | $50.85 | 2024-2025 | |
| Puma Biotechnology, INC. | $47.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $45.40 | 2025 | |
| Boston Scientific Corporation | $45.22 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Genzyme Corporation | $43.53 | 2025 | |
| Glaxosmithkline, LLC. | $36.70 | 2025 | Jemperli, Ojjaara |
| Celgene Corporation | $32.37 | 2025 | Reblozyl |
| Emd Serono, INC. | $30.54 | 2025 | |
| Stemline Therapeutics INC. | $30.14 | 2025 | Orserdu |
| Genentech USA, INC. | $29.92 | 2025 | Venclexta |
| Geron Corporation | $29.91 | 2025 | Rytelo |
| Eisai INC. | $29.01 | 2025 | |
| Rigel Pharmaceuticals, INC. | $28.51 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Aveo Pharmaceuticals, INC. | $27.96 | 2025 | |
| Recordati_rare_diseases_inc. | $27.36 | 2025 | Sylvant |
| Iovance Biotherapeutics, INC. | $24.99 | 2025 | Amtagvi |
| Alexion Pharmaceuticals, INC. | $24.62 | 2025 | Ultomiris |
| Legend Biotech USA INC. | $23.25 | 2025 | Carvykti |
| Ipsen Biopharmaceuticals, INC | $22.54 | 2025 | Onivyde |
| Azurity Pharmaceuticals, INC. | $22.45 | 2025 | Danziten |
| Sumitomo Pharma America, INC. | $20.15 | 2025 | Orgovyx |
| Pharmacosmos Therapeutics INC. | $19.12 | 2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $18.24 | 2025 | |
| Gilead Sciences, INC. | $14.62 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahe Otero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.